Edap Tms SA
NASDAQ:EDAP

Watchlist Manager
Edap Tms SA Logo
Edap Tms SA
NASDAQ:EDAP
Watchlist
Price: 3.44 USD 0.58% Market Closed
Market Cap: $128.6m

P/B

4.8
Current
28%
More Expensive
vs 3-y average of 3.7

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
4.8
=
Market Cap
$129.4m
/
Total Equity
€23.3m

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
4.8
=
Market Cap
$129.4m
/
Total Equity
€23.3m

Valuation Scenarios

Edap Tms SA is trading above its 3-year average

If P/B returns to its 3-Year Average (3.7), the stock would be worth $2.69 (22% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-79%
Maximum Upside
No Upside Scenarios
Average Downside
46%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 4.8 $3.44
0%
3-Year Average 3.7 $2.69
-22%
5-Year Average 4.1 $2.93
-15%
Industry Average 1 $0.71
-79%
Country Average 1.5 $1.06
-69%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close

Market Distribution

Higher than 85% of companies in France
Percentile
85th
Based on 1 681 companies
85th percentile
4.8
Low
0 — 0.9
Typical Range
0.9 — 2.6
High
2.6 —
Distribution Statistics
France
Min 0
30th Percentile 0.9
Median 1.5
70th Percentile 2.6
Max 185.9

Edap Tms SA
Glance View

Market Cap
128.6m USD
Industry
Health Care

EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 227 full-time employees. The firm operates worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. The firm invests in Research & Development, partnering with INSERM French public laboratory and international medical research institutions. Company's activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). The firm is developing HIFU technology (High Intensity Focused Ultrasound) in non-invasive treatment of prostate conditions with its range of Robotic HIFU devices, Ablatherm Fusion and Focal One. The firm is also developing ESWL (Extracorporeal ShockWave Lithotripsy) and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications.

EDAP Intrinsic Value
3.98 USD
Undervaluation 13%
Intrinsic Value
Price $3.44
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett